TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Hamilton Depression Rating Scale (HAMD)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in ALS Functional Rating Scale- Revised (ALSFRS-R) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of Atrial Fibrillation/Atrial Flutter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Risk of febrile neutropenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Risk of neutropenia grade 3/4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of participants with grade 3 acute toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Survival at 1 year after treatment
Endpoint domain: Mortality/survival
Primary endpoint: Sensitivity to cane sugar
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone turnover markers level-β-C terminal telopeptid (β-CTX)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Peak pressure at lateral forefoot
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative patient-controlled analgesic demand
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate to erlotinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Event related potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metacognition questionnaire-30 (MCQ-30)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Ketone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: safety and efficacy of intracoronary infusion of NBS10
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With Dose-limiting Toxicities (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Serum Potassium Level Through 12 Weeks of Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Adverse Events of Participants Taking Patiromer
Endpoint domain: Adverse events/effects
Primary endpoint: Knee Society Score Evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total number of radiologic failures of the device
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence Rate of Hypoglycemia During and After Moderate to High Intensity Aerobic Exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean Number of Hypoglycemic Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean Number of Qualified High Intensity Aerobic Exercise Sessions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Alleviation of Cough
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time to Alleviation of Body Temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distal bowel cleansing performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiac-related hospital readmissions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Plasma malondialdehyde
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma 8-isoprostane F2-alpha
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma tumor necrosis factor alpha
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Plasma interleukin 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Plasma C-reactive protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Plasma MCP-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from baseline Maximum voluntary contraction (MVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change from baseline Concentric Torque
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: sclerostin level response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hernia recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: occurrence of PPH
Endpoint domain: Adverse events/effects
Primary endpoint: Unaided LogMAR visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Low back pain assessed with Visual Analog Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Low back pain assessed with Balanced Inventory for Spinal Disorders (BIS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Low back pain assessed with Oswestry Disability Index (ODI)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Low back pain assessed with Short-Form-36 (SF-36)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Surface temperature of face and hand
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of narcotics in first 24 hours
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Patients With Serum Total Bilirubin <1.5 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients With Native Liver
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skindex-16 score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: C-reactive protein serum concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Body mass index percentile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction of postoperative emesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion of dilated eye examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in lung parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Urinary level of total NNAL (nmol/mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of successful percutaneous localization and removal of PPN
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of the localization procedure
Endpoint domain: Adverse events/effects
Primary endpoint: Number of enrollment cases
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: a-posteriori sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Urticaria Activity Score (% Change From Baseline)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiac output/index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Numeric risk recognition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain intensity measured by Visual Analogue Scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Absolute Change From Study Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in severity of crow's feet
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Serum concentrations of TREM-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum concentrations of CCL-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum concentrations of MMP-9
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum concentrations of OPN
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum concentrations of IL-1RA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Citrulline concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Duration of Overall Survival
Endpoint domain: Mortality/survival
Primary endpoint: Number of participants with pancreatitis
Endpoint domain: Adverse events/effects
Primary endpoint: Agreement of CC diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Disagreement of CC diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Days of supplementary oxygen if applies
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Forced Expiratory Volume in one second z score (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Median change in total lean body mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median change in handgrip strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Whole blood glucose level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Burning Pain Induced by Topical Capsaicin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Numeric rating scale (NRS)
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Circulating MicroRNAs measurement in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of feet with signs of osteoarthritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Plasma area under curve (AUC) of SPH3127
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Cmax of SPH3127
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Tmax of SPH3127
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent terminal half-life of SPH3127
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aggregate Annualized Relapse Rate (ARR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to complete re-epithelialization of the palatal wound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 12-month incidence of all Serious Adverse Events in Subjects
Endpoint domain: Adverse events/effects
Primary endpoint: 12-month incidence of falls and fall-associated injuries
Endpoint domain: Adverse events/effects
Primary endpoint: 12-month incidence of all Serious Adverse Events in Companions
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of Subjects enrolled in training who successfully complete the intended training
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of Subjects who demonstrate proficiencies at 12 months after completion of training
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Subjects' abilities to navigate surfaces and environments outside of the institutional environment
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Major hemorrhagic event
Endpoint domain: Adverse events/effects
Primary endpoint: Papillary volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Opioid Use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Dietary patterns including egg consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Flare Occurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Flare-to-visit Time
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: infant HIV positive PCR at six months postpartum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: mother lost to follow-up at six months postpartum
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Half-life of 6β-Naltrexol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic profile of 6β-Naltrexol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to First Administration of Pain Medication After Block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sum of peak torques
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Clinical success of vital pulp therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hamilton Rating Scale for Depression (HRSD-25)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time to Maximum Plasma Concentration of Motesanib (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration of Motesanib (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Estimated Terminal-phase Half-life (t1/2,z) of Motesanib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of catheter dysfunction requiring intervention
Endpoint domain: Adverse events/effects
Primary endpoint: 25OHD level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Adverse Events Related to Treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Cost-Effectiveness
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Difficult laryngoscopy classification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total clinical failure rate of condoms
Endpoint domain: Adverse events/effects
Primary endpoint: Increase in stroke volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in tumor volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Fugl-Meyer Assessment upper extremity part (FMA) between baseline and 6th week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Fugl-Meyer Assessment upper extremity part (FMA) between 6th week and 12th week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in System Usability Scale between 6th week and 12th week
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: CPEAK, AUCL, and AUCI ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With 2-hour Pain Free Active Study Drug
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Migraine Attacks With Sustained Pain Free Response From 2 to 24 Hours Post-Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Migraine Attacks With Pain Free Response at 2 Hours Post-Dose Following Early Intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum tolerated dose (MTD)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Adverse Events (AEs) - Relapsed/Refractory Population
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With AEs - First-line Population
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With RSV-associated Hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Percent Change in Reward-related Brain Activation as Measured by fMRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Reward-related Brain Activation as Measured by EEG Ratio of Beta to Theta Power
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Causes of fetal death
Endpoint domain: Mortality/survival
Primary endpoint: AUC0-tz of BI 1467335
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of BI 1467335
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scoring Atopic Dermatitis (SCORAD) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of days required for wound healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Cognitive functions assessment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Percent decrease of AGT in CTCL skin lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: MTD of carmustine
Endpoint domain: Adverse events/effects
Primary endpoint: Reproductive risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Drug Acceptability, as Measured by Number of Participants With Dose-limiting Side Effects
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Self-reported Side Effects
Endpoint domain: Adverse events/effects
Primary endpoint: Cognitive Changes Over Time, as Measured by Between Group and Within-subjects Comparison of Neuropsychological Measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Learning Motivation Scale
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Self-Confidence Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Academic Achievement Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hip X ray assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VISA activity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events assessments
Endpoint domain: Adverse events/effects
Primary endpoint: Total Disappearance of All Warts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Size of calcific deposit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immediate hemodynamic effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Functional neurological outcomes at 6 months based on Extended Glasgow Outcome Scale (GOS-E)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite complete response (CR) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Composite CR rate with partial hematologic recovery (CRh) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Nominal Change in Coronary Percent Atheroma Volume (PAV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of Change in Carotid Intima-media Thickness (CIMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Weight of the infant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of the infant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body Mass Index (BMI) of the infant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parasitological cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Recipient patient and graft survival
Endpoint domain: Mortality/survival
Primary endpoint: Health Related Quality of Life (HRQOL) in living liver donors
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number and severity of surgical complications
Endpoint domain: Adverse events/effects
Primary endpoint: Anatomical improvement according to POP-Q score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evaluation of radiation-induced mucositis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Acute Toxicity: Radiation pneumonitis
Endpoint domain: Adverse events/effects
Primary endpoint: Wheal size area (mm2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: number of errors on the Groton Maze Learning Test (GMLT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mean Clinical Global Impression Severity Score (CGI-S)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Six-month Progression Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Anxiety Sensitivity Index-3
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Delta Thrombingeneration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of subjects achieving glycemic response (HbA1c < 7.0%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Progression-Free Survival (PFS) at 3 Years
Endpoint domain: Mortality/survival
Primary endpoint: Change in Left Ventricular Ejection Fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes